| HOME >> BIOLOGY >> TECHNOLOGY |
Time (Poster): 8 a.m.-noon Location: W375e Lobby
Time (Discussion): Noon-1 p.m. Location: W375a
Poster Number: 5 Abstract Number: 3528
Presenter: Heather A. Wakelee, MD
-- XL880* (MET, VEGFR2) -- Poster
"A phase 2 study of the dual MET/VEGFR2 inhibitor GSK1363089 (XL880)
in patients with papillary renal carcinoma (PRC)"
Day: Saturday, May 31
Session: Genitourinary Cancer
Time: 8 a.m.-noon
Location: S Hall A1
Poster Number: 5G Abstract Number: 5103
Presenter: Ramiprasad Srinivasan, MD, PhD
-- XL765 (PI3K, mTOR) -- Oral Presentation
"A phase 1 dose-escalation study of the safety, pharmacokinetics
(PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765,
administered orally to patients (pts) with advanced solid tumors"
Day: Saturday, May 31
Session: PI-3 Kinase/mTOR Directed Agents
Time: 1:45-2:15 pm
Location: W375a
Abstract Number: 3510
Presenter: Kyriakos Papadopoulis, MD
* XL880 was selected by GlaxoSmithKline in December 2007 for further
development and commercialization.
Sunday, June 1
-- XL184 (RET, MET, VEGFR2) -- Oral Presentation
"A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor,
in patients (pts) with advanced malignancies, including pts with
medullary thyroid cancer (MTC)"
Day: Sunday, June 1
Session: Developmental Therapeutics: Molecular Therapeutics
Time: 10-10:15 a.m.
Location: W375a
Abstract Number: 3522
Presenter: Ravi Salgia, MD, PhD
-- XL647 (EGFR, HER2, VEGFR2) -- Poster
"Activity of XL647 in clinically selected NSCLC patients (pts)
'/>"/>| SOURCE Exelixis, Inc. Copyright©2008 PR Newswire. All rights reserved |